Clinical Trial

A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 52-week period.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-13; most recent amendment 2026-03-26.
Trial Details
NCT Number NCT07126262
Lead Sponsor BioMarin Pharmaceutical
Collaborators: ICON Clinical Research
Conditions Hypochondroplasia
Enrollment 60 participants
Start Date 2025-07-30
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-31